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Patients with juvenile idiopathic arthritis (JIA) can experience a severe disease course, with
progressive destructive polyarthritis refractory to conventional therapy with disease-
modifying antirheumatic drugs including biologics, as well as life-threatening complications
including macrophage activation syndrome (MAS). Allogeneic hematopoietic stem cell
transplantation (allo-HSCT) is a potentially curative immunomodulatory strategy for patients
with such refractory disease.We treated 16patients in 5 transplant centers between2007 and
2016: 11 childrenwith systemic JIA and 5with rheumatoid factor–negative polyarticular JIA;
all were either refractory to standard therapy, had developed secondary hemophagocytic
lymphohistiocytosis/MAS poorly responsive to treatment, or had failed autologous HSCT. All
children received reduced toxicity ﬂudarabine-based conditioning regimens and serother-
apy with alemtuzumab. Fourteen of 16 patients are alive with a median follow-up of 29
months (range, 2.8-96 months). All patients had hematological recovery. Three patients had
grade II-IV acute graft-versus-host disease. The incidence of viral infections after HSCT was
high, likely due to the use of alemtuzumab in already heavily immunosuppressed patients.
All patients had signiﬁcant improvement of arthritis, resolution of MAS, and improved
quality of life early following allo-HSCT; most importantly, 11 children achieved complete
drug-free remission at the last follow-up. Allo-HSCT using alemtuzumab and reduced
toxicity conditioning is a promising therapeutic option for patients with JIA refractory to
conventional therapy and/or complicated by MAS. Long-term follow-up is required to
ascertain whether disease control following HSCT continues indeﬁnitely.
Introduction
Systemic juvenile idiopathic arthritis (sJIA) is characterized by arthritis associated with prominent
systemic features such as fever, skin rash, serositis, lymphadenopathy, hepatosplenomegaly, and
increased inflammatory markers. Clinical outcome is generally poor if symptoms are not well
controlled1,2; ;10% of patients with sJIA develop life-threatening complications such as macrophage
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activation syndrome (MAS), which has a reported mortality of 8%
in this context, and/or severe life-threatening infections due to
prolonged immunosuppressive treatment with multiple agents.3-6
The main goal of immunosuppressive and anti-inflammatory
treatment strategies in sJIA is to achieve disease remission while
trying to minimize drug-related toxicity. There are multiple treatment
options, including nonsteroidal anti-inflammatory drugs, corticoste-
roids, disease-modifying antirheumatic drugs (DMARDs) such as
methotrexate (MTX), and a variety of biologics targeting key
inflammatory cytokines.7 Although most children with sJIA respond
to conventional therapy, a small proportion of patients either do not
achieve disease remission or experience significant drug-related
side effects.8 This can lead to long-term sequelae including
permanent joint damage, osteoporosis, growth retardation, and
reduced quality of life.7,9 Autologous hematopoietic stem cell
transplantation (HSCT) has been assessed as a therapeutic option
for children with refractory sJIA since 1997, as an experimental
strategy to reset the dysregulated immune system and eliminate
autoreactive T cells.9 A number of studies have demonstrated that
children undergoing a T-cell–depleted autologous HSCT for
refractory JIA, majority with sJIA, can achieve complete drug-free
remission.10-14 However, in some cases, disease remission is of
transient duration, as a significant proportion of children relapse
with inflammatory symptoms after autologous transplant, proba-
bly due to reemerging autoreactive T lymphocytes.15 Moreover,
T-cell–depleted autologous HSCT is associated with significant
mortality, due to prolonged and severe depression of T-cell
immunity, leading to viral infections and MAS.11-13
Allogeneic HSCT (allo-HSCT) has potential advantages in this
context, with the goal of achieving life-long disease remissions by
replacement of the patients’ dysregulated immune system.16,17
Conversely, allo-HSCT introduces the significant risk of graft-
versus-host-disease (GVHD). Data on allo-HSCT performed in
children with autoimmune diseases and in particular JIA, are
extremely scarce.18-20 Here, we report the outcomes of 16 children
with severe, refractory JIA who underwent allo-HSCT in 5 different
centers between 2007 and 2016.
Methods
Patients and methods
This retrospective observational cohort describes the outcomes of
16 children with refractory JIA: 11 children with sJIA and 5 with
rheumatoid factor (RF)-negative polyarticular JIA (poly-JIA) who
underwent allo-HSCT in 5 different centers between April 2007
and March 2016. The centers participating in this study were
Great Ormond Street Hospital, London, United Kingdom (n 5 5);
Great North Children’s Hospital, Newcastle upon Tyne, United
Kingdom (n 5 5); University College Hospital, London, United
Kingdom (n 5 2); Teaching Hospital Motol, Prague, Czech
Republic (n 5 1); and Cincinnati Children’s Hospital Medical
Center (CCHMC), Cincinnati, OH (n 5 3).
Medical charts were reviewed and the following data were
extracted from each case using a standardized form: patient
demographics, classification of JIA subtype, treatments prior to
HSCT, indication for HSCT, donor-recipient matching, conditioning
regimen, and graft composition. Posttransplantation data were
collected on count recovery, immune reconstitution, lineage-
specific chimerism, occurrence of GVHD, infections, and relapse
of initial (or occurrence of new, secondary, post-HSCT) autoimmu-
nity. All patients were enrolled in their local institutional review
board–approved protocol or treatment plan. Written informed
consent was obtained from the parents or legal guardians of all
patients prior to the initiation of conditioning therapy for trans-
plantation. Information regarding patient 1 has been previously
published.12
Data are presented in terms of frequency and central tendency
measures (means and medians). All patients had HLA medium- or
high-resolution typing for the following loci: class I (HLA A, B, C)
and class II (HLA DQ, DRB1). Patients were considered refractory
to treatment if they had active disease that failed to respond to
multiple lines of treatment including 2 or more biologics or
unacceptable adverse reaction to corticosteroids or biologics.
Complete response (CR) post-HSCT was defined as complete
resolution of arthralgia or arthritis and no recurrence of disease
symptoms after stopping immunosuppression (IS). Partial re-
sponse (PR) was defined as: (1) significant clinical improvement




Patients’ characteristics are summarized in Table 1. The median age
at diagnosis was 21.5 months (range, 5 months to 12 years),
whereas the median age at transplant was 8.4 years (range, 2.6-16
years). Patients received a median of 5 (range, 2-9) lines of
immunomodulatory treatment before HSCT, specifically 9 of them
received tocilizumab, and all children were considered refractory to
treatment. Five patients had suffered life-threatening complications
pre-HSCT. Indication for transplant was: (1) unresponsiveness to
standard therapy and biologics (n5 10), (2) failed autologous stem
cell transplant (n 5 1), or (3) secondary hemophagocytic
lymphohistiocytosis (HLH)/MAS, poorly responsive to treatment
(n5 5). None of the patients with MAS had a molecular diagnosis of
familial HLH.
Transplant procedure
Transplant characteristics are summarized in Table 2. Patients
underwent allo-HSCT from a 10 of 10 or 12 of 12 HLA matched
unrelated donor (n 5 9), 9 of 10 HLA mismatched unrelated donor
(n 5 3), or 10 of 10 HLA matched sibling donor (n 5 4). All patients
received a reduced toxicity conditioning regimen with fludarabine 30
mg/m2 per day (from days 7 to 3), melphalan 140 mg/m2 (day 3),
alemtuzumab 0.2 mg/kg per day (from days 8 to 4) (n 5 10) or
fludarabine 30 mg/m2 per day (from days 8 to 4), treosulfan 14 g/m2
per day (from days 6 to 4), alemtuzumab 0.2 mg/kg per day (from days
8 to 4) (n56).Of theCCHMCpatients, patient 2 received alemtuzumab
0.2mg/kg per day, days 22 to 18,whereas patients 13 and14 received it
days 14 to 10. All 3 patients received fludarabine 30mg/m2 per day from
days 8 to 4 and melphalan 140 mg/m2 on day 3. Peripheral blood was
the stem cell source in the majority of cases (n 5 12).
Most patients received cyclosporine (CsA) and mycophenolate
mofetil (MMF) as GVHD prophylaxis (n 5 10). All patients received
antiviral, antifungal, and antibacterial prophylaxis during transplant
according to the local policies. The median CD341 cell dose infused
was 9.23 106/kg (range, 1.7-32.23 106/kg) and the median CD31
cell dose was 3.2 3 108/kg (range, 0.26-15.5 3 108/kg).
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All patients had hematological recovery. The median time to
neutrophil recovery .0.5 3 109/L was 13 days (range, 10-65
days), while the median time to platelet recovery .20 3 109/L was
15 days (range, 9-87 days).
With a median follow-up of 29 months (range, 2.8-8 years), 14 of 16
patients were alive: patient 1 died of probable sepsis 20 months
posttransplant following an elective procedure to replace the right
patella while still on immunosuppressive treatment of chronic
GVHD and patient 2 died of invasive fungal infection in the context
of grade III aGVHD, 85 days posttransplant, giving a transplant
related mortality (TRM) of 12.5%.
TRM
Infections. The incidence of viral infections/reactivation was
high; details are reported in Table 2. Three patients developed
shingles, 1 patient experienced Guillain-Barre´ syndrome associated
with varicella zoster virus reactivation and HHV6 enteritis, while 6
patients developed adenoviremia requiring antiviral medications or
treatment with adenovirus-specific T cells (patient 4 and patient 11).
Two patients developed EBV viremia requiring treatment with
rituximab (patients 1 and 9) and 2 patients had CMV reactivation
leading to pneumonitis in 1 case (patient 3). One patient developed
BKV encephalitis (patient 1). There was 1 case each of Serratia
fasciitis (patient 11) and of infection with atypical mycobacteria
(patient 3). Two patients experienced severe bacterial infections
and 1 child presented disseminated life-threatening fungal disease
(patient 2).
GVHD. Three patients experienced grade II-IV acute GVHD
(aGVHD). There was 1 patient with extensive chronic GVHD (patient 1)
at the last follow-up. On balance, patient 12 and patient 16 were
considered to have recurrent disease post-HSCT as both presented
with active polyarthritis, but distinguishing recurrent disease from chronic
GVHD in this setting can be very difficult.
JIA outcome and donor engraftment. The median number
of affected joints pretransplant was 12 (range, 3-70 joints) whereas
posttransplant 4 patients had active joint inflammation: patient 5
had a reduced number of joints affected (feet, knees, hands, and
shoulders) compared with 39 joints affected pretransplant; patient
9 had 1 active joint transiently; patient 12 had a reduced number of
joints from almost all joints affected to 8 joints and patient 16 had
polyarthritis following cessation of IS as shown in Figure 1. At last
follow-up, 11 of 14 surviving patients were in complete remission
(symptom-free and off immunosuppressants), 2 of 4 surviving
patients with poly-JIA and 9 of 10 with sJIA. Patient 5 achieved
complete remission posttransplant sustained after cessation of IS
but had relapse of arthritis and uveitis 5 years post-HSCT requiring
intra-articular corticosteroids and tocilizumab. Patient 12 had
chronic severe active disease prior to HSCT, which was refractory
to immunosuppressive treatment: she was immobile, fully de-
pendent on her mother, and unable to take care of herself. After
transplant, she experienced a significant clinical improvement: at
last follow-up, she was physically active, walking and with no pain,
although she was still dependent on corticosteroids and MMF.
Patient 9, who had sJIA and MAS prior to his HSCT, presented 22
months following the allo-HSCT with fevers, skin rash, and arthralgia
in 1 joint. This was treated with a brief course of corticosteroids,
with complete resolution of the symptoms. He was in CR and
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synovitis as corticosteroids were tapered 2 months post-HSCT but
responded to an increased dose of corticosteroids; at 6 months
post-HSCT, as CsA was stopped, she presented with fevers,
polyarthritis, cytopenias (all 3 lineages), raised ferritin, and in-
flammatory markers but did not 100% fulfill the MAS criteria. At
the same time, she dropped the percentage of naive T cells with
significant increase in activated DR1 T cells, although with high
levels of donor chimerism in CD15 and CD3 lineages. She was
treated with pulsed methylprednisolone, high-dose immunoglobulin,
rituximab, and anakinra with relatively good response but ongoing
joint inflammation.
Results of donor engraftment were available in 15 of 16 children
(Figure 2). Eight children achieved 100% donor engraftment in
peripheral blood, whereas 6 patients who had chimerism monitored
in different cell lineages (T cells, B cells, myeloid cells) expressed very
high levels of donor engraftment in their T-cell compartment (median,
86%; range,,10%-95%) and myeloid compartment (median, 90%;
range, 0%-97%). There was no obvious correlation between the level
of myeloid or T-cell donor engraftment and disease outcome,
exemplified by patient 12, who in spite of 100% donor engraftment
achieved only PR, patient 5 who despite of 100% donor engraftment
relapsed late post-HSCT, patient 16 who relapsed after stopping IS
despite high levels of donor engraftment in both lymphoid and
myeloid lineages, and patient 10 who remains in CR in spite of 0%
myeloid and only low-level T-cell donor engraftment.
The median time to the withdrawal of IS was 7 months (range, 4-24
months).
Figure 3 shows the pattern of T-cell and B-cell reconstitution after
transplant. T-cell reconstitution was generally slow, with a median
time to achieve a CD41 T-cell count $0.3 3 109/L of 12 months
(range, 6-15 months).
Figure 4 shows the pattern of erythrocyte sedimentation rate (ESR)
pre- and post-allo-HSCT. The levels pre-HSCT were not very high,
probably due to immunomodulation pretransplant. Although not all
centers assessed ESR following HSCT, there was a trend to
reduced ESR post-HSCT.
Autoimmunity. Five patients developed secondary autoim-
munity posttransplant, mainly cytopenias, and were responsive to
short courses of IS. Patient 3 developed severe pancytopenia
requiring 2 CD341 cell infusions, as well as IVIG, rituximab,
eltrombopag and eventually splenectomy; patient 13 developed
immune thrombocytopenia requiring rituximab, whereas patient 8
experienced immune-mediated neutropenia and thrombocytopenia
treated with IVIG, corticosteroids, rituximab, and MMF.21 Patient 5
developed severe but transient Guillain-Barre´ syndrome. Patient 15
developed transient thyrotoxicosis evolving to hypothyroidism.
Discussion
Children affected by JIA can experience significant morbidity associated
with poorly controlled disease and long-term immunosuppressive
treatment, in particular serious infections, neuropsychiatric adverse
events, autoimmunity, and an increased risk of malignancy.3,5,22-25
Over the past decade, the experience with autologous stem cell
transplantation (ASCT) for patients with refractory JIA has produced
valuable data. The biological mechanisms by which ASCT works were
shown to be not only by the eradication of autoreactive lymphocytes
with immunosuppressive conditioning and T-cell depletion, but also
importantly by restoration of the chimeric T-cell receptor (TCR)
repertoire and CD41CD251 T regulatory cells.26-29 Rates of drug-free
remission were between 50% and 57%.13,30 However, in a
prospective follow-up of the initial multicenter study,11 12 of 20
patients relapsed between 2 and 16 months posttransplant and 1
patient relapsed 7 years following ASCT.12 The mechanism of relapse
was hypothesized to have occurred due to insufficient lymphoablation
and clonally skewed TCR repertoire26 or due to recurrence of
activated effector CD41 T lymphocytes (autoreactive lymphocytes).15
Moreover, the initial mortality associated with the procedure was high
at 9% as 2 patients died of MAS early post-ASCT11 and a similar high
mortality rate was reported at a later stage from the United Kingdom
experience.13 This high TRM was attributed to the combination of
significant T-cell depletion and infection.11-13,18
Considering that the pathogenesis of sJIA is very similar to known
genetic autoinflammatory diseases affecting mostly the innate
immune system,31,32 there might be a theoretical advantage of
allogeneic stem cell transplant compared with ASCT. Allogeneic
stem cell transplant in animal models has been shown to generate
intrathymic tolerance more effectively when compared with
autologous transplantation.33 Moreover, allogeneic stem cell trans-
plantation has the potential for a graft-versus-autoimmune
effect,16,33 documented in a series of patients who underwent
HSCT for hematological conditions and concomitant autoimmune
diseases.34-39 Somewhat unexpectedly, the results of both the
European experience (1984-2007)40 and a United Kingdom
national analysis (1997-2009) of allo-HSCT for severe autoimmune
diseases showed 55% CR and 23% PR in the European database,
and sustained responses in 60% to 70% of patients undergoing
allo-HSCT compared with 30% to 40% of patients undergoing
autologous HSCT in the United Kingdom database.18
Following our initial report,19 we describe the outcomes of reduced
intensity allogeneic transplantation for JIA in a multicenter cohort of 16
pediatric patients in a 9-year period.With the follow-up duration ranging
from 85 days to 8 years, we observed an overall survival of 87.5%. At
last follow-up, 11 of 14 surviving patients were in CR (symptom free
and off immunosuppressants), 1 was in PR, and 2 had active disease
(1 late relapse and 1 relapse after cessation of immunosuppressants).
In this complex cohort of patients where allo-HSCT was performed
relatively late in the course of the disease, TRM was expectedly high

































Figure 1. Average number of affected joints pre-HSCT and at last follow-up.
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T-cell–depleted HSCT.11,13 There was a high incidence of viral
infections and/or viral reactivation, not unexpected in the context of in
vivo T-cell–depleted transplantation. We did observe the occurrence
of secondary autoimmunity post-HSCT, mainly cytopenias, which did
not require prolonged treatment as has been previously reported.41
Selecting eligible patients for allo-HSCT earlier in the course of their
progressive disease rather than leaving it as the “last resort”42,43 could
significantly improve the outcome, in particular by reducing morbidity
from potentially life-threatening infections and preventing the devel-
opment of severe joint damage and consequent complications.
For those rare patients presenting with potential life-threatening
complications such as pulmonary hypertension and/or MAS44 the
indication may be more straightforward. However, for patients with
otherwise uncomplicated but refractory disease, that is, those not
responding to multiple conventional or biologic DMARDs, defining
the correct indications for allogeneic transplantation remains a
challenge.32 At the present time there are several studies assessing
potential biomarkers and specific molecular defects associated with
a severe disease phenotype and response to therapy.45,46 While
those are validated, indication for HSCT is defined individually and
according to the experience of the center, as this approach is still an
experimental therapy.42,47 Normalization of raised serum interleukin-
18 (IL-18) levels has recently been demonstrated posttransplant,
hence serum IL-18 may potentially be a useful biomarker to assess
disease activity of sJIA in this context.48,49
Of note, a potential disadvantage of allo-HSCT following a failed
autologous procedure is the possibility of adding comorbidities,
especially from severe infections (eg, patient 1). The indications for
and the role of allo-HSCT for treating children with JIA may be better
defined once genetic defects or biomarkers associated with severe
phenotypes of the disease are revealed.
Pt1
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Figure 2. Engraftment of patients who underwent allogeneic stem cell transplantation at 3, 6, and 12 months and at the last follow-up.
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Despite reduced intensity conditioning, all patients engrafted donor cells
in all cell lineages except 1 patient who underwent a mismatched
unrelated donor transplant and only engrafted donor T cells. It is not
known at this stage whether there will be an impact of mixed chimerism
on the ongoing remission status of the disease posttransplantation. In
this cohort of patients, full donor chimerism was not always associated
with remission: 1 patient with 100% donor cell engraftment had only
partial response with ongoing inflammation of big joints requiring low-
dose corticosteroids and MMF 12 months posttransplant, 2 patients
with high-level donor cell engraftment have active disease at last follow-
up (1 relapsed late posttransplant [patient 5] and 1 patient relapsed
following cessation of IS 6 months posttransplant), whereas another
patient with only partial T-cell engraftment remains in CR 17 months
posttransplant. The mechanism of remission in the latter patient is
possibly due to self-tolerance of autoreactive T cells, mirroring that in the
autologous HSCT setting.27 Similar to the results from the ASCT
experience, we presume that significant joint damage prior to transplant
is not reversible with the procedure even despite full donor chimerism.15
As this was an observational retrospective study, there were
limitations relating to the availability of data to fully assess JIA
disease activity pre- and post-HSCT using the core set criteria.50
For this study, we were only able to collect data on joint counts and
ESR (Figures 1 and 4, respectively).
In conclusion, we show that reduced intensity HSCT for severe,
refractory JIA is a safe and effective procedure to rescue patients that
did not respond despite being heavily treated, or those who developed
complications associated with MAS. However, to reduce TRM and
morbidities, mainly infections, we favor considering early HSCT for those
eligible patients with a suitable available donor avoiding prolonged use of
immunosuppressive medications and preventing severe and potentially
irreversible joint damage, and/or treatment-associated burden of disease
mainly growth retardation, hypertension, and osteoporosis due to
prolonged corticosteroid usage. Prospective studies are warranted to
harmonize selection of patients and indications for transplant, to evaluate
conditioning regimens that could promote robust engraftment with even
lower toxicity, to assess potential biomarkers, and to investigate
immunological mechanisms of remission following allo-HSCT.
Clearly, longer follow-up is required to confirm the effectiveness
of allo-HSCT for severe, refractory JIA as late relapse has been
observed in this setting. As JIA is a complex group of disorders, it is
of paramount importance that the follow-up post-HSCT includes a
multidisciplinary team (transplant, rheumatology, immunology, and
physiotherapy specialties) following standardized methods. This
would facilitate better assessment of disease response, better
evaluation of the role of HSCT in the therapeutic algorithm, and
indicate whether there is any difference in the outcomes between
the subtypes of the disease.
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Figure 3. Median T-cell and B-cell counts following allo-HSCT for JIA.
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Figure 4. ESR pre- and post-HSCT. Data available for 15 patients pre-HSCT; for
patients 1, 2, 3, 9, 11, and 16 at 3 months post-HSCT; for patients 1, 6, 9, and 11
at 6 months post-HSCT; for patients 1, 2, 8, 9, and 11 at 9 months post-HSCT, and
for patients 1, 2, 6, 9, and 11 at 12 months post-HSCT.
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